david marash-whitman 11/20/13. kpc (klebsiella pneumoniae carbapenemase) 18 infected patients 6...

15
STRATEGY FOR COMBATTING THE RISE OF DRUG- RESISTANT BACTERIA IN THE US David Marash-Whitman 11/20/13

Upload: isabel-preston

Post on 31-Dec-2015

218 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

STRATEGY FOR COMBATTING THE

RISE OF DRUG-RESISTANT

BACTERIA IN THE US

David Marash-Whitman11/20/13

Page 2: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence
Page 3: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

KPC(Klebsiella

pneumoniaecarbapenemase)

18 infected patients

6 fatalities

complete drug resistance

persistent presence at

NIH center

Page 4: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE PROBLEM

increased usage leadsto decreased future effectiveness

antibiotics are being used excessively

development of new antibioticsis expensive

finite source of future antibiotics

Page 5: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

promote conservative use of antibiotics

incentive to comply

remove barriers to compliance

Page 6: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

bioethical responsibility

timeliness affordability

Page 7: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

bioethical responsibility

timeliness affordability

Page 8: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

bioethical responsibility

timeliness affordability

Page 9: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

promote conservative use of antibiotics

increase incentive to comply

remove barriers to compliance

Page 10: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

Prove-It SepsisSeptifast Sepsitest

$50

6 hours

25 species

$75

3.5 hours

70 species

$125

<1 hour

345 species

Page 11: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

bioethical responsibility

timeliness affordability

Page 12: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

THE SOLUTION

bioethical responsibility

timeliness affordability

Page 13: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

OUTCOMES

accessibility of medical technology

reduction of inappropriateantibiotic prescriptions

Page 14: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence
Page 15: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence

SHORT TERMPREVENTION LONG TERM

general health

vaccination

development ofnew antibiotics

conservative useof antibiotics(in humans)(in animals)

development ofnew antimicrobial

therapies